NEW YORK, Aug. 20, 2019 (GLOBE NEWSWIRE) — Faruqi & Faruqi, LLP, a leading national securities law firm, reminds investors in Evolent Health, Inc. (“Evolent Health, Inc.” or the “Company”) (NYSE: EVH) of the October 7, 2019 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company.
If you invested in Evolent stock or options between March 3, 2017 and May 28, 2019 and would like to discuss your legal rights, click here: www.faruqilaw.com/EVH. There is no cost or obligation to you.
You can also contact us by calling Richard Gonnello toll free at 877-247-4292 or at 212-983-9330 or by sending an e-mail to [email protected]
FARUQI & FARUQI, LLP
685 Third Avenue, 26th Floor
New York, NY 10017
Attn: Richard Gonnello, Esq.
Telephone: (877) 247-4292 or (212) 983-9330
The lawsuit has been filed in the U.S. District Court for the Eastern District of Virginia on behalf of all those who purchased Evolent securities between March 3, 2017 and May 28, 2019 (the “Class Period”). The case, Plymouth County Retirement System v. Evolent Health, Inc. et al., Docket No. 1:19-cv-01031 was filed on August 8, 2019 and has been assigned to Judge Rossie D. Alston, Jr.
The lawsuit focuses on whether the Company and its executives violated federal securities laws by making false and/or misleading statements and/or failing to disclose that: (1) Evolent’s partnership model did not align the Company’s interests with those of its partners, as the model was designed to inflate the Company’s revenue by extracting enormous administrative and management fees at the expense of its operating partners such as Passport; (2) Passport was struggling financially, particularly after Kentucky cut its reimbursement rates, and the partnership between Evolent and Passport was becoming increasingly unsustainable; (3) Evolent was draining Passport of functions, employees and money, to such an extent that Passport was left on the verge of insolvency; and (4) Passport was conducting a bidding process for several months to sell itself to prevent liquidation.
On this news, Evolent’s stock fell from $14.15 on May 28, 2019 to $10.01 on May 29, 2019—a $4.14 or a 29.26% drop.
The court-appointed lead plaintiff is the investor with the largest financial interest in the relief sought by the class who is adequate and typical of class members who directs and oversees the litigation on behalf of the putative class. Any member of the putative class may move the Court to serve as lead plaintiff through counsel of their choice, or may choose to do nothing and remain an absent class member. Your ability to share in any recovery is not affected by the decision to serve as a lead plaintiff or not.
Faruqi & Faruqi, LLP also encourages anyone with information regarding Evolent’s conduct to contact the firm, including whistleblowers, former employees, shareholders and others.
Attorney Advertising. The law firm responsible for this advertisement is Faruqi & Faruqi, LLP (www.faruqilaw.com). Prior results do not guarantee or predict a similar outcome with respect to any future matter. We welcome the opportunity to discuss your particular case. All communications will be treated in a confidential manner.
Latest posts by GlobeNewswire (see all)
- Old National reports 4th quarter earnings, announces dividend increase, stock repurchase plan, and ONB Way strategic update - January 21, 2020
- REGO Payment Architectures, Inc. Announces Launch Customer to Deliver its COPPA Compliant Digital Wallet - January 21, 2020
- E-Cigarette Market revenue to hit USD 9 Bn by 2026: Global Market Insights, Inc. - January 21, 2020